Back to Search
HEATHER BEALL, M.D.
M.D.
Obstetrics & Gynecology Physician
NPI: 1447202577IndividualAccepts Medicare
Specialties, Licenses & Credentials
Obstetrics & Gynecology PhysicianPrimary
Obstetrics & Gynecology
Code: 207V00000X
036-109230(IL)
CMS Specialties
PrimaryOBSTETRICS/GYNECOLOGY
Education
UNIVERSITY OF ILLINOIS COLLEGE OF MED (CHI/PEOR/ROCK/CHM-URB)
Class of 1989
Research & Publications (18)
Bis-anthracenyl isoxazolyl amides have enhanced anticancer activity.
PMID 19560922·Bioorg Med Chem Lett·2009
8-other
Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies.
PMID 18457384·J Med Chem·2008
8-other
Indolequinone antitumour agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase.
PMID 17571194·Org Biomol Chem·2007
8-other
Activation of protein kinase C and disruption of endothelial monolayer integrity by sodium arsenite--Potential mechanism in the development of atherosclerosis.
PMID 17306850·Toxicol Appl Pharmacol·2007
8-other
Arsenic exposure in pregnant mice disrupts placental vasculogenesis and causes spontaneous abortion.
PMID 17569693·Toxicol Sci·2007
7-preclinical
Benzimidazole- and benzothiazole-quinones: excellent substrates for NAD(P)H:quinone oxidoreductase 1.
PMID 17971996·Org Biomol Chem·2007
8-other
Manganese enhances peroxynitrite and leukotriene E4 formation in bovine aortic endothelial cells exposed to arsenic.
PMID 16845179·Cardiovasc Toxicol·2006
7-preclinical
Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1.
PMID 16302813·J Med Chem·2005
8-other
Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).
PMID 15028260·Bioorg Med Chem·2004
8-other
Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis.
PMID 15519606·Toxicol Appl Pharmacol·2004
7-preclinical
Topical delivery of 5-fluorouracil (5-FU) by 1,3-bisalkylcarbonyl-5-FU prodrugs.
PMID 11719012·Int J Pharm·2002
4-observational
Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents.
PMID 12549859·Angiogenesis·2002
4-observational
Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis.
PMID 12392964·Toxicol Appl Pharmacol·2002
7-preclinical
Indolequinone antitumor agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Part 2.
PMID 11563930·J Med Chem·2001
8-other
Topical delivery of 5-fluorouracil (5-Fu) by 3-alkylcarbonyl-5-Fu prodrugs.
PMID 11292549·Int J Pharm·2001
7-preclinical
Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development.
PMID 10877993·Front Biosci·2000
6-review
NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms.
PMID 11154736·Chem Biol Interact·2000
6-review
Hydrogen-deuterium exchange in decaborane(14): mechanistic studies.
PMID 12526574·Inorg Chem·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 3 locations total
- Address
- 260 E CONGRESS PKWY
CRYSTAL LAKE, IL 60014 - Phone
- (815) 477-0300
Quick Facts
- NPI
- 1447202577
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 3
- Years in Practice
- 37
- Publications
- 18
Are you this provider?
Claim Your Profile